Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
42
IFRX Quote, Financials, Valuation and Earnings
Last price:
$2.24
Seasonality move
:
8.86%
Day range:
$2.08 - $2.29
52-week range:
$1.17 - $2.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
716.25x
P/B ratio:
1.81x
Volume:
87.5K
Avg. volume:
430.8K
1-year change:
50.67%
Market cap:
$132.2M
Revenue:
$68.3K
EPS (TTM):
-$1.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$84.1K | -$0.27 | 5602.11% | -2.23% | $8.04 |
|
AFMD
Affimed NV
|
$1.5M | -$1.06 | -50.03% | -42.4% | $18.90 |
|
ATAI
ATAI Life Sciences NV
|
-- | -$0.16 | 1288.89% | -36.36% | -- |
|
BNTX
BioNTech SE
|
$561.1M | -$1.75 | -24.68% | -74.38% | $137.54 |
|
CVAC
CureVac NV
|
$150.6M | $1.54 | -66% | -69.73% | $7.38 |
|
IMTX
Immatics NV
|
$17.4M | -$0.28 | -11.96% | -3.68% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$2.25 | $8.04 | $132.2M | -- | $0.00 | 0% | 716.25x |
|
AFMD
Affimed NV
|
$1.18 | $18.90 | $19.3M | -- | $0.00 | 0% | 19.11x |
|
ATAI
ATAI Life Sciences NV
|
$1.19 | -- | $199.7M | -- | $0.00 | 0% | -- |
|
BNTX
BioNTech SE
|
$113.08 | $137.54 | $27.1B | 184.86x | $0.00 | 0% | 8.26x |
|
CVAC
CureVac NV
|
$2.89 | $7.38 | $647.2M | 5.26x | $0.00 | 0% | 1.09x |
|
IMTX
Immatics NV
|
$6.85 | -- | $832.6M | -- | $0.00 | 0% | 5.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-- | 4.286 | -- | 4.34x |
|
AFMD
Affimed NV
|
31.93% | 0.815 | 16.35% | 1.76x |
|
ATAI
ATAI Life Sciences NV
|
13.5% | 2.808 | 11.65% | 4.73x |
|
BNTX
BioNTech SE
|
1.26% | 0.543 | 0.96% | 7.10x |
|
CVAC
CureVac NV
|
-- | 2.309 | -- | 6.10x |
|
IMTX
Immatics NV
|
-- | 1.740 | -- | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$216K | -$16.9M | -61.55% | -61.55% | -14084.63% | -$11.2M |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
ATAI
ATAI Life Sciences NV
|
-- | -$22.6M | -56.15% | -61.19% | -64200% | -$19.3M |
|
BNTX
BioNTech SE
|
$1.2B | $11.5M | -2.32% | -2.35% | 13.39% | -$770.2M |
|
CVAC
CureVac NV
|
$519.1M | $404.1M | 21.3% | 21.3% | 75.06% | $381.2M |
|
IMTX
Immatics NV
|
-- | $565.3K | -16.88% | -16.88% | -4.19% | -$42M |
InflaRx NV vs. Competitors
-
Which has Higher Returns IFRX or AFMD?
Affimed NV has a net margin of -14092.9% compared to InflaRx NV's net margin of -9767.12%. InflaRx NV's return on equity of -61.55% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.33 $72.9M AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About IFRX or AFMD?
InflaRx NV has a consensus price target of $8.04, signalling upside risk potential of 258.31%. On the other hand Affimed NV has an analysts' consensus of $18.90 which suggests that it could grow by 1499.1%. Given that Affimed NV has higher upside potential than InflaRx NV, analysts believe Affimed NV is more attractive than InflaRx NV.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV3 1 0 AFMDAffimed NV5 1 0 -
Is IFRX or AFMD More Risky?
InflaRx NV has a beta of 1.675, which suggesting that the stock is 67.534% more volatile than S&P 500. In comparison Affimed NV has a beta of 2.063, suggesting its more volatile than the S&P 500 by 106.315%.
-
Which is a Better Dividend Stock IFRX or AFMD?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or AFMD?
InflaRx NV quarterly revenues are $136.2K, which are smaller than Affimed NV quarterly revenues of $170.5K. InflaRx NV's net income of -$19.2M is lower than Affimed NV's net income of -$16.7M. Notably, InflaRx NV's price-to-earnings ratio is -- while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 716.25x versus 19.11x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV716.25x -- $136.2K -$19.2M AFMDAffimed NV19.11x -- $170.5K -$16.7M
-
Which has Higher Returns IFRX or ATAI?
ATAI Life Sciences NV has a net margin of -14092.9% compared to InflaRx NV's net margin of -65715%. InflaRx NV's return on equity of -61.55% beat ATAI Life Sciences NV's return on equity of -61.19%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.33 $72.9M ATAIATAI Life Sciences NV-- -$0.16 $169.1M -
What do Analysts Say About IFRX or ATAI?
InflaRx NV has a consensus price target of $8.04, signalling upside risk potential of 258.31%. On the other hand ATAI Life Sciences NV has an analysts' consensus of -- which suggests that it could grow by 572.27%. Given that ATAI Life Sciences NV has higher upside potential than InflaRx NV, analysts believe ATAI Life Sciences NV is more attractive than InflaRx NV.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV3 1 0 ATAIATAI Life Sciences NV0 0 0 -
Is IFRX or ATAI More Risky?
InflaRx NV has a beta of 1.675, which suggesting that the stock is 67.534% more volatile than S&P 500. In comparison ATAI Life Sciences NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or ATAI?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ATAI Life Sciences NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. ATAI Life Sciences NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or ATAI?
InflaRx NV quarterly revenues are $136.2K, which are larger than ATAI Life Sciences NV quarterly revenues of $40K. InflaRx NV's net income of -$19.2M is higher than ATAI Life Sciences NV's net income of -$26.3M. Notably, InflaRx NV's price-to-earnings ratio is -- while ATAI Life Sciences NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 716.25x versus -- for ATAI Life Sciences NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV716.25x -- $136.2K -$19.2M ATAIATAI Life Sciences NV-- -- $40K -$26.3M
-
Which has Higher Returns IFRX or BNTX?
BioNTech SE has a net margin of -14092.9% compared to InflaRx NV's net margin of 15.91%. InflaRx NV's return on equity of -61.55% beat BioNTech SE's return on equity of -2.35%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.33 $72.9M BNTXBioNTech SE85.63% $0.89 $21.6B -
What do Analysts Say About IFRX or BNTX?
InflaRx NV has a consensus price target of $8.04, signalling upside risk potential of 258.31%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 21.63%. Given that InflaRx NV has higher upside potential than BioNTech SE, analysts believe InflaRx NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV3 1 0 BNTXBioNTech SE11 5 0 -
Is IFRX or BNTX More Risky?
InflaRx NV has a beta of 1.675, which suggesting that the stock is 67.534% more volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.
-
Which is a Better Dividend Stock IFRX or BNTX?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or BNTX?
InflaRx NV quarterly revenues are $136.2K, which are smaller than BioNTech SE quarterly revenues of $1.4B. InflaRx NV's net income of -$19.2M is lower than BioNTech SE's net income of $217.9M. Notably, InflaRx NV's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 716.25x versus 8.26x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV716.25x -- $136.2K -$19.2M BNTXBioNTech SE8.26x 184.86x $1.4B $217.9M
-
Which has Higher Returns IFRX or CVAC?
CureVac NV has a net margin of -14092.9% compared to InflaRx NV's net margin of 68.44%. InflaRx NV's return on equity of -61.55% beat CureVac NV's return on equity of 21.3%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.33 $72.9M CVACCureVac NV95.56% $1.65 $809.4M -
What do Analysts Say About IFRX or CVAC?
InflaRx NV has a consensus price target of $8.04, signalling upside risk potential of 258.31%. On the other hand CureVac NV has an analysts' consensus of $7.38 which suggests that it could grow by 153.19%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV3 1 0 CVACCureVac NV3 4 0 -
Is IFRX or CVAC More Risky?
InflaRx NV has a beta of 1.675, which suggesting that the stock is 67.534% more volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or CVAC?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or CVAC?
InflaRx NV quarterly revenues are $136.2K, which are smaller than CureVac NV quarterly revenues of $543.2M. InflaRx NV's net income of -$19.2M is lower than CureVac NV's net income of $371.8M. Notably, InflaRx NV's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 716.25x versus 1.09x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV716.25x -- $136.2K -$19.2M CVACCureVac NV1.09x 5.26x $543.2M $371.8M
-
Which has Higher Returns IFRX or IMTX?
Immatics NV has a net margin of -14092.9% compared to InflaRx NV's net margin of -16.95%. InflaRx NV's return on equity of -61.55% beat Immatics NV's return on equity of -16.88%.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.33 $72.9M IMTXImmatics NV-- -$0.12 $427.2M -
What do Analysts Say About IFRX or IMTX?
InflaRx NV has a consensus price target of $8.04, signalling upside risk potential of 258.31%. On the other hand Immatics NV has an analysts' consensus of -- which suggests that it could grow by 144.53%. Given that InflaRx NV has higher upside potential than Immatics NV, analysts believe InflaRx NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV3 1 0 IMTXImmatics NV6 0 0 -
Is IFRX or IMTX More Risky?
InflaRx NV has a beta of 1.675, which suggesting that the stock is 67.534% more volatile than S&P 500. In comparison Immatics NV has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.688%.
-
Which is a Better Dividend Stock IFRX or IMTX?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or IMTX?
InflaRx NV quarterly revenues are $136.2K, which are smaller than Immatics NV quarterly revenues of $55.6M. InflaRx NV's net income of -$19.2M is lower than Immatics NV's net income of -$9.4M. Notably, InflaRx NV's price-to-earnings ratio is -- while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 716.25x versus 5.50x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV716.25x -- $136.2K -$19.2M IMTXImmatics NV5.50x -- $55.6M -$9.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
